Antiviral Reduced Transmission of Influenza to Close Contacts
Baloxavir may have potential use in an influenza pandemic before a vaccine is developed
Related Articles
The FDA’s new approach to COVID vaccines.
A spontaneous chat in The Doctor’s Lounge covering some breaking news, with Dr. Céline Gounder and Dr. Jeremy Faust.
FDA significantly limits COVID-19 vaccine recommendations
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 The US Food and Drug Administration (FDA) announced today that it will only recommend COVID-19 vaccines for adults 65 and…
Family likely infected with histoplasmosis in bat-colonized cave
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000
FDA Plans to Limit COVID-19 Vaccines to High-Risk Groups
The agency, under new leadership, is rethinking who should get the vaccine.
Trump officials set new requirements for COVID vaccines in healthy adults and children
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy.
Wiki-What? Navigating WikiGuidelines and Leveraging Their Advantages
WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.
The hidden cost of retesting vaccines
A reader asked me a question I get semi-regularly about vaccine skeptics:
Inside the rise of Tracy Beth Høeg, the Covid contrarian shaping FDA vaccine policy
Høeg has been skeptical of the safety and value of some vaccines and mandates, raising questions about her approach at the FDA.
In historic move, WHO Member States approve 20% funding increase and 2026–27 budget
In a show of support for a sustainably financed World Health Organization, WHO Member States today approved a 20% increase in assessed contributions (membership dues)…
FDA will restrict future COVID-19 vaccines based on age, risk factors
FDA officials outlined new restrictions for COVID-19 vaccine approvals in the United States that could limit their use among healthy people.
